Connect your AI

aTyr Pharma ATYR Change in receivables

Change in receivables at other companies

Bristol-Myers SquibbBMY

-$1.69B-11,147%

Syndax PharmaceuticalsSNDX

-$6.14M-13,538%

LQD

Liquidia CorporationLQDA

$20.06M+1,463%

Other financials

Income statement

Revenue-—

Operating income-$11.4M+27.5%

Net income-$10.8M+27.5%

EPS (diluted)-$0.11+35.3%

Balance sheet

Cash & equivalents$10.0M-3.4%

Total debt$12.3M-9.2%

Total equity$57.9M-22.8%

Total assets$79.7M-18.1%

Cash flow

Operating cash flow-$12.5M+18.8%

CapEx$138.0K—

Free cash flow-$12.7M+17.9%

Valuation

Market cap$54.88M-88.2%

Enterprise value$57.17M—

P/S288.8×—

Profitability

Operating margin-40,856.3%+28,833pp

Net margin-39,009.5%+29,653pp

FCF margin-32,664.7%+4,018pp

Returns & leverage

Return on equity-105.3%+50.6pp

Debt / equity0.2×0.0×

Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is aTyr Pharma's change in receivables?: aTyr Pharma (ATYR) reported change in receivables of -$396K in Q1 2026.
How has aTyr Pharma's change in receivables changed year-over-year?: aTyr Pharma's change in receivables increased by 47.1% year-over-year, from -$748K to -$396K.
What does change in receivables mean?: Change in total receivables including trade and non-trade receivables.